Osteoarthritis (OA), a chronic degenerative joint disease, will affect an increasing number of individuals as the population ages. It is only recently that pain, the main cause of complaint from patients, has become a source of interest. This thesis investigates a chemical model of knee osteoarthritis pain induced by intra-articular injection of monosodium iodoacetate, an inhibitor of glycolysis. After validating this model and developing new behavioural tests to assess mechanical and cooling hypersensitivity as well as ambulatory-evoked pain, the effects of existing analgesics such as morphine and gabapentin following chronic administration were studied. Both agents decreased pain behaviour but with different time-courses. Using the same t...
The main symptom of osteoarthritis (OA) is chronic pain. In many cases, this pain can be explained b...
Objectives Nerve growth factor (NGF) is a promising analgesic target, particularly in osteoarthritis...
Osteoarthritis (OA) is expected to become the fourth leading cause of disability worldwide by 2020. ...
More than 10 million adults consult their GP each year with arthritis and related conditions. Signif...
Abstract Background Clinical studies of osteoarthritis (OA) suggest central sensitization may contri...
SummaryObjectiveOsteoarthritis (OA) is a complex and painful disease of the whole joint. At present ...
OBJECTIVE: Pain is the main reason patients report Osteoarthritis (OA), yet current analgesics remai...
The mechanisms underlying the transition from acute nociceptive pain to centrally maintained chronic...
Osteoarthritis (OA) is a chronic joint disorder whose principal symptom is chronic pain. Current ana...
AbstractObjective: To describe an in vivo model in the rat in which change in weight distribution is...
ObjectivesTo address the hypothesis that different types of established OA pain behaviours have asso...
The treatment of chronic, inflammatory pain in humans is still unsatisfactory. In order to develop n...
Osteoarthritis is the most common musculoskeletal disease worldwide, characterized by degradation of...
Joint degeneration observed in the rat monoiodoacetate (MIA) model of osteoarthritis shares many his...
SummaryObjectivesTo address the hypothesis that different types of established osteoarthritis (OA) p...
The main symptom of osteoarthritis (OA) is chronic pain. In many cases, this pain can be explained b...
Objectives Nerve growth factor (NGF) is a promising analgesic target, particularly in osteoarthritis...
Osteoarthritis (OA) is expected to become the fourth leading cause of disability worldwide by 2020. ...
More than 10 million adults consult their GP each year with arthritis and related conditions. Signif...
Abstract Background Clinical studies of osteoarthritis (OA) suggest central sensitization may contri...
SummaryObjectiveOsteoarthritis (OA) is a complex and painful disease of the whole joint. At present ...
OBJECTIVE: Pain is the main reason patients report Osteoarthritis (OA), yet current analgesics remai...
The mechanisms underlying the transition from acute nociceptive pain to centrally maintained chronic...
Osteoarthritis (OA) is a chronic joint disorder whose principal symptom is chronic pain. Current ana...
AbstractObjective: To describe an in vivo model in the rat in which change in weight distribution is...
ObjectivesTo address the hypothesis that different types of established OA pain behaviours have asso...
The treatment of chronic, inflammatory pain in humans is still unsatisfactory. In order to develop n...
Osteoarthritis is the most common musculoskeletal disease worldwide, characterized by degradation of...
Joint degeneration observed in the rat monoiodoacetate (MIA) model of osteoarthritis shares many his...
SummaryObjectivesTo address the hypothesis that different types of established osteoarthritis (OA) p...
The main symptom of osteoarthritis (OA) is chronic pain. In many cases, this pain can be explained b...
Objectives Nerve growth factor (NGF) is a promising analgesic target, particularly in osteoarthritis...
Osteoarthritis (OA) is expected to become the fourth leading cause of disability worldwide by 2020. ...